Focus: Tango Therapeutics is an oncology-focused biotech company developing novel cancer immunotherapies and targeted approaches. The company operates from Cambridge, MA with a pipeline spanning non-small cell lung cancer, solid tumors, and breast cancer indications.
Profile data last refreshed 46m ago · AI intelligence enriched 2w ago
Growing — net +7 jobs in 30d
12 jobs added vs 5 removed. Steady team buildout.
Tango offers meaningful early-stage oncology science and development exposure, but career stability depends entirely on investor appetite and clinical success in competitive immuno-oncology space.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tango Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tango Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 Bitget
symbol__ Stock Quote Price and Forecast - CNN
symbol__ Stock Quote Price and Forecast CNN
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Tango Therapeutics: Promising Early Data, But A Long Road Ahead Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX MarketBeat
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles